35 clinical trials found.
-
A Phase 1/2 Open-Label Multi-Center First-in-Human Study of the Safety Tolerability Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements (TRIDENT-1)
The purpose of this Phase 1/2 research study is to test the effects of an investigational study drug called repotrectinib for the possible treatment ...Phase
TRIAL ROLE: Principal Investigator
-
A PHASE 1B OPEN-LABEL MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PRELIMINARY EFFICACY OF NKTR 214 IN COMBINATION WITH ANTI-PD-1 (PEMBROLIZUMAB) FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC MELANOMA LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER OR METASTATIC NON-S ALL CELL LUNG CANCER
If you have been diagnosed with locally advanced or metastatic (the spread of) melanoma, locally advanced or metastatic (the spread of) urothelial bladder cancer or ...
Phase
TRIAL ROLE: Principal Investigator
-
A Phase 2 Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
The purpose of the study is to determine how well different drugs work in a single type of cancer for patients with advanced NSCLC. This ...Phase
TRIAL ROLE: Principal Investigator
-
Phase 1 and phase 2a first-in-human study of DRP-104 a glutamine antagonist in adult patients with advanced solid tumors
The purpose of the study is to assess safety, tolerability, and antitumor activity of DRP-104 administered via intravenous infusion as a single agent and in ...Phase
TRIAL ROLE: Principal Investigator
-
A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB or IV Non-Small Cell Lung Cancer
The purpose of the study is to evaluate niraparib plus pembrolizumab versus placebo plus pembrolizumab in participants with advanced or metastatic nonsmall cell lung cancer ...Phase
TRIAL ROLE: Principal Investigator
-
A Phase 2 Multicenter Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-line Treatment (CodeBreaK 201)
The purpose of the study is to determine the anti-tumor effect (safety and tolerability) of sotorasib monotherapy in subjects with metastatic non-small cell lung cancer ...Phase
TRIAL ROLE: Principal Investigator
-
An Open Label First in Human (FIH) Phase 1 Trial of LVGN6051 as Single Agent and in Combination with Keytruda (pembrolizumab) in Advanced or Metastatic Malignancy
The purpose of the study is to look at how your body tolerates LVGN6051, how safe LVGN6051 may be, and how LVGN6051 is taken up ...Phase
TRIAL ROLE: Principal Investigator
-
An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-na ve EGFR-mutant Locally Advanced or Metastatic NSCLC
The purpose of this study is to find out whether the addition of ramucirumab to osimertinib is better at controlling EGFR lung cancer than just ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
The purpose of this study is to test the safety, tolerability, and effectiveness of MRTX849 (called “the study drug” from now on) for advanced cancers ...Phase
TRIAL ROLE: Sub Investigator
-
A Phase 1/2 Open-Label Dose-Escalation Safety and Tolerability Study of NC318 in Subjects with Advanced or Metastatic Solid Tumors
The purpose of this research study is to learn about the effects of the study drug, NC318, when given as an investigational combination treatment for ...Phase
TRIAL ROLE: Sub Investigator
